TY - JOUR T1 - Prophylactic dose fondaparinux for 6 weeks in superficial thrombophlebitis of the legs reduces the risk for symptomatic thromboembolic complications JF - Evidence Based Medicine JO - Evid Based Med SP - 28 LP - 29 DO - 10.1136/eb-2012-100755 VL - 18 IS - 1 AU - Maria T DeSancho AU - Stephen M Pastores Y1 - 2013/02/01 UR - http://ebm.bmj.com/content/18/1/28.abstract N2 - Commentary on: Di Nisio M, Wichers IM, Middeldorp S. Treatment for superficial thrombophlebitis of the leg. Cochrane Database Syst Rev 2012;3:CD004982.OpenUrlPubMed Superficial thrombophlebitis (ST), an inflammatory-thrombotic disorder in a superficial vein, is relatively common and estimated to occur in 1 per 1000 persons.1 The classic symptoms include pain, oedema, erythema and occasionally a palpable cord in the area of the thrombosed vein. Risk factors for ST include surgery, pregnancy and puerperium, female hormones, malignancy, infection, varicose veins, autoimmune disorders and thrombophilia.2 ST is a risk factor for deep venous thrombosis (DVT); 12–44% of patients with ST develop a DVT.3 The treatment of ST is highly variable ranging from no treatment to treatments with non-steroidal anti-inflammatory drugs, … ER -